Literature DB >> 34004484

Circulating ceramides as biomarkers of cardiovascular disease: Evidence from phenotypic and genomic studies.

Kathryn A McGurk1, Bernard D Keavney2, Anna Nicolaou3.   

Abstract

There is a need for new biomarkers of atherosclerotic cardiovascular disease (ACVD), the main cause of death globally. Ceramides, a class of potent bioactive lipid mediators, have signalling roles in apoptosis, cellular stress and inflammation. Recent studies have highlighted circulating ceramides as novel biomarkers of coronary artery disease, type-2 diabetes and insulin resistance. Ceramides are highly regulated by enzymatic reactions throughout the body in terms of their activity and metabolism, including production, degradation and transport. The genetic studies that have been completed to date on the main ceramide species found in circulation are described, highlighting the importance of DNA variants in genes involved in ceramide biosynthesis as key influencers of heritable, circulating ceramide levels. We also review studies of disease associations with ceramides and discuss mechanistic insights deriving from recent genomic studies. The signalling activities of ceramides in vascular inflammation and apoptosis, associations between circulating ceramides and coronary artery disease risk, type-2 diabetes and insulin resistance, and the potential importance of ceramides with regard to ACVD risk factors, such as blood pressure, lipoproteins and lifestyle factors, are also discussed.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Ceramides; Genetics

Year:  2021        PMID: 34004484     DOI: 10.1016/j.atherosclerosis.2021.04.021

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  Associations of NAFLD with circulating ceramides and impaired glycemia.

Authors:  Meghana D Gadgil; Monika Sarkar; Caroline Sands; Matthew R Lewis; David M Herrington; Alka M Kanaya
Journal:  Diabetes Res Clin Pract       Date:  2022-03-12       Impact factor: 8.180

2.  Individuals with Metabolic Syndrome Show Altered Fecal Lipidomic Profiles with No Signs of Intestinal Inflammation or Increased Intestinal Permeability.

Authors:  Mia J Coleman; Luis M Espino; Hernan Lebensohn; Marija V Zimkute; Negar Yaghooti; Christina L Ling; Jessica M Gross; Natalia Listwan; Sandra Cano; Vanessa Garcia; Debbie M Lovato; Susan L Tigert; Drew R Jones; Rama R Gullapalli; Neal E Rakov; Euriko G Torrazza Perez; Eliseo F Castillo
Journal:  Metabolites       Date:  2022-05-11

Review 3.  Role of Ceramides in the Molecular Pathogenesis and Potential Therapeutic Strategies of Cardiometabolic Diseases: What we Know so Far.

Authors:  Youssef M Shalaby; Anas Al Aidaros; Anjana Valappil; Bassam R Ali; Nadia Akawi
Journal:  Front Cell Dev Biol       Date:  2022-01-19

Review 4.  Sex Differences in Cardiovascular Diseases: A Matter of Estrogens, Ceramides, and Sphingosine 1-Phosphate.

Authors:  Beatrice Arosio; Graziamaria Corbi; Sergio Davinelli; Vienna Giordano; Daniela Liccardo; Antonio Rapacciuolo; Alessandro Cannavo
Journal:  Int J Mol Sci       Date:  2022-04-04       Impact factor: 5.923

Review 5.  Ceramides as Mediators of Oxidative Stress and Inflammation in Cardiometabolic Disease.

Authors:  Melania Gaggini; Rudina Ndreu; Elena Michelucci; Silvia Rocchiccioli; Cristina Vassalle
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

6.  Genetic Variants Associated with Elevated Plasma Ceramides in Individuals with Metabolic Syndrome.

Authors:  Sanghoo Lee; Seol-A Kim; Yejin Kim; Juhoon Kim; Gayeon Hong; Jeonghoon Hong; Kyeonghwan Choi; Chun-Sick Eom; Saeyun Baik; Mi-Kyeong Lee; Kyoung-Ryul Lee
Journal:  Genes (Basel)       Date:  2022-08-22       Impact factor: 4.141

7.  Genetic Architecture of Untargeted Lipidomics in Cardiometabolic-Disease Patients Combines Strong Polygenic Control and Pleiotropy.

Authors:  Francois Brial; Lyamine Hedjazi; Kazuhiro Sonomura; Cynthia Al Hageh; Pierre Zalloua; Fumihiko Matsuda; Dominique Gauguier
Journal:  Metabolites       Date:  2022-06-27

Review 8.  There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.

Authors:  Michael E Makover; Michael D Shapiro; Peter P Toth
Journal:  Am J Prev Cardiol       Date:  2022-08-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.